AI assistant
CHIMERIC THERAPEUTICS LIMITED — Regulatory Filings 2021
May 23, 2021
64648_rns_2021-05-23_9ded7f1b-feef-481b-b5ab-f09c009aa6a5.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
ASX ANNOUNCEMENT ASX ANNOUNCEMENT 24 MAY 2021 24 MAY 2021
==> picture [7 x 16] intentionally omitted <==
==> picture [7 x 15] intentionally omitted <==
==> picture [7 x 15] intentionally omitted <==
==> picture [7 x 15] intentionally omitted <==
==> picture [61 x 90] intentionally omitted <==
SECOND DOSE COHORT INITIATED IN CLTX CAR T PHASE 1 TRIAL
HIGHLIGHTS
-
The 1[st] patient in the 2[nd] dose cohort of the CLTX CAR T cell clinical trial at the City of Hope, a worldrenowned cancer treatment and research center near Los Angeles, has received dosing
-
Dosing of the 2[nd] dose cohort introduced dual intratumoral and intraventricular routes of dosing
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company, is pleased to announce the treatment of the first patient in the second dose cohort in City of Hope’s phase 1 clinical trial evaluating the safety and tolerability of Chimeric’s chlorotoxin CAR T (CLTX CAR T) cell therapy.
The treatment of the first patient in the second dose cohort marks the introduction of dual routes of administration of CLTX CAR T cells with both intracranial intratumoral (ICT) and intracranial intraventricular (ICV) dosing. This second dose cohort will receive a total target dose of 88 × 10[6] CLTX CAR T cells. City of Hope’s phase 1 clinical trial is expected to enroll 18-36 patients with MMP2+ progressive or recurrent glioblastoma over a 24month period.
“We are very encouraged by the continued progress of the trial, moving to this important next phase with dose escalation and dual routes of administration,” said Jennifer Chow, Chimeric Therapeutics Chief Operating Officer. “This is another significant milestone in the development of this important therapy for patients with progressive or recurrent glioblastoma.”
Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.
ABOUT CHLOROTOXIN CAR T CELLS
Chlorotoxin CAR T (CLTX CAR T) cell therapy is a potentially best in class CAR T cell therapy that has the potential to address the high unmet medical need of patients with recurrent / progressive glioblastoma (GBM). Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope.
CLTX CAR T cell therapy uniquely utilises chlorotoxin (CLTX), a peptide derived from scorpion toxin, as the tumor targeting component of the chimeric antigen receptor (CAR). CLTX has been shown in preclinical models to bind more broadly and specifically to GBM cells than other targets like EGFR, HER2 or IL13Rα2.
In preclinical models, CLTX CAR T cells also demonstrated potent antitumor activity against GBM while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile.
ABOUT CHIMERIC THERAPEUTICS
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for patients with cancer.
CHIMERIC THERAPEUTICS LIMITED | 1
LEVEL 3, 62 LYGON STREET CARLTON VIC 3053, AUSTRALIA
Chimeric believes that cellular therapies have the potential to cure cancer and that by combining their expertise in the development and commercialization of cell therapies with the world’s most innovative scientists and science, they will be able to bring the promise of cell therapy to life for more patients.
Chimeric Therapeutics has licensed the exclusive global rights to intellectual property covering the CLTX CAR T cell therapy which is currently in development for patients with progressive and recurrent glioblastoma and is also being investigated for development in patients with other solid tumors such as melanoma, small cell lung cancer, prostate cancer and colorectal cancer.
Chimeric Therapeutics is also currently actively engaged in enhancing their pipeline with innovative cell therapies for patients with cancer.
CONTACT
Investors
Jennifer Chow Chief Operating Officer P: 908-723-8387
Media
Matthew Wright NWR Communications P: +61 451 896 420
LEVEL 3, 62 LYGON STREET CARLTON VIC 3053, AUSTRALIA
CHIMERIC THERAPEUTICS LIMITED | 2